Drug
Methylnaltrexone clinical trials
Also written Relistor, MOA-728 and MNTX.
- studies test it
- 59
- open now
- 2
- in phase 3
- 12
- first study started
- 2002
Keep track of what changes. Save the methylnaltrexone studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
59 studies that test it; most in 2007 (10)
| Year | Studies |
|---|---|
| 2002 | 3 |
| 2003 | 3 |
| 2004 | 2 |
| 2005 | 1 |
| 2006 | 9 |
| 2007 | 10 |
| 2008 | 4 |
| 2009 | 7 |
| 2010 | 6 |
| 2011 | 1 |
| 2013 | 2 |
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 1 |
| 2017 | 1 |
| 2019 | 1 |
| 2020 | 3 |
| 2021 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 23
- Phase 2
- 11
- Phase 3
- 12
- Phase 4
- 12
- No phase
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 40 · Other 19
Bausch Health Americas, Inc. (39) · University Medicine Greifswald (2) · Region Örebro County (2) · University of Missouri-Columbia (1) · Ohio State University (1) · Karolinska University Hospital (1) · University of Florida (1) · Universitaire Ziekenhuizen KU Leuven (1)
Often tested with
Tested in the same studies.
Naloxone (3) · Naloxegol (1) · Codeine (1) · Erythromycin (1)
Studies
Open first, then newest update. How each study uses methylnaltrexone is read from its arms, and is right about nine times in ten.
Testing it · 59
- Chronic Widespread Pain in HIV: Novel Mechanisms and TherapeuticsRecruitingNot applicableFlorida International UniversityNCT04787848Written as Relistor Injectable Product
- Methylnatrexone In Resectable Head and Neck Squamous Cell Carcinoma (MINK). A "Window of Opportunity" Pilot Study.RecruitingPhase 4M.D. Anderson Cancer CenterNCT06162377Written as Methylnaltrexone
- Methylnaltrexone vs Naloxegol in the Treatment of Opioid-Induced ConstipationCompletedPhase 4University of Missouri-ColumbiaNCT03523520Written as Methylnaltrexone Bromide 150 mg Oral Tablet
- Naloxone and Intravenous Methylnaltrexone Effects on Bladder FunctionCompletedPhase 1Bausch Health Americas, Inc.NCT01367561Written as IV Methylnaltrexone (MNTX)
- Subcutaneous Methylnaltrexone Versus Placebo for Postoperative Ileus PreventionCompletedPhase 2Ohio State UniversityNCT03852524Written as Methylnaltrexone
- An Extension Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic CancerWithdrawnPhase 3Bausch Health Americas, Inc.NCT04151719Written as Methylnaltrexone bromide (MNTX)
- A Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic CancerWithdrawnPhase 2/3Bausch Health Americas, Inc.NCT04083651Written as Methylnaltrexone bromide
- Study Evaluating MOA-728 Oral for the Treatment of OIBD in Subjects With Chronic Non-Malignant PainCompletedPhase 2Bausch Health Americas, Inc.NCT00605644Written as MOA-728
- Study Evaluating Oral MOA-728 For The Treatment Of OIBD In Subjects With Chronic Non-Malignant PainCompletedPhase 2Bausch Health Americas, Inc.NCT00547586Written as N-methylnaltrexone bromide (MOA-728)
- Study Evaluating the Efficacy and Safety of Subcutaneous Methylnaltrexone (MOA-728) for the Treatment of Opioid-Induced-ConstipationCompletedPhase 3Bausch Health Americas, Inc.NCT00936884Written as Methylnaltrexone
- Evaluate the Pharmacokinetics (PK) of Methylnaltrexone (MNTX) in Healthy Adult SubjectsCompletedPhase 1Bausch Health Americas, Inc.NCT01366326Written as Methylnaltrexone bromide
- Effect of Methylnaltrexone (MNTX) on Electrocardiogram (ECG) Parameters and Cardiac RepolarizationCompletedPhase 1Bausch Health Americas, Inc.NCT01363323Written as Methylnaltrexone (MNTX)
- Study Evaluating MOA-728 Administered in Healthy MenWithdrawnPhase 1Bausch Health Americas, Inc.NCT00427258Written as MOA-728
- Study Evaluating Oral MOA-728 in Subjects on Methadone TherapyWithdrawnPhase 1Bausch Health Americas, Inc.NCT00505583Written as MOA-728
- Study Evaluating Safety & Efficacy of Subcutaneous Methylnaltrexone on Opioid-Induced Constipation in Cancer SubjectsWithdrawnPhase 4Bausch Health Americas, Inc.NCT00858754Written as methylnaltrexone
- Intravenous (IV) Methylnaltrexone (MNTX) in the Prevention of Post-Operative IleusCompletedPhase 2Bausch Health Americas, Inc.NCT01367548Written as IV Methylnaltrexone (MNTX)
- Study of Pharmacokinetics, Safety and Tolerability of Intravenous Methylnaltrexone BromideCompletedPhase 1Bausch Health Americas, Inc.NCT01366365Written as methylnaltrexone
- Tolerance and Pharmacokinetics Study of MNTX TabletsCompletedPhase 1Bausch Health Americas, Inc.NCT01366339Written as Oral methylnaltrexone
- Effects of MNTX on CYP450 2D6 in Metabolizers of DextromethorphanCompletedPhase 1Bausch Health Americas, Inc.NCT01367535Written as IV Methylnaltrexone (MNTX)
- Pharmacokinetics and Bioavailability of Single Subcutaneous Doses of Methylnaltrexone Versus Intravenous DoseCompletedPhase 1Bausch Health Americas, Inc.NCT01367496Written as IV Methylnaltrexone (MNTX)
See all 59 studies that test methylnaltrexone →
Given in every arm · 1 — methylnaltrexone is usual care beside what is tested
Codes
What other systems call methylnaltrexone · ClinicalTrials.gg INT002974
- MeSH (NLM) C032257methylnaltrexoneConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 0RK7M7IABEMETHYLNALTREXONEConfirmed FDA, NLM
- RxNorm 29899One source FDA
- NCI Thesaurus C48403MethylnaltrexoneOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C032257 | methylnaltrexone | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 0RK7M7IABE | METHYLNALTREXONE | Confirmed FDA, NLM |
| RxNorm | 29899 | — | One source FDA |
| NCI Thesaurus | C48403 | Methylnaltrexone | One source FDA |
Also registered as methylnaltrexone bromide (UNII RFO6IL3D3M · RxNorm 979111).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.